Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Procrit Once-Weekly Labeling Resubmitted To FDA

Executive Summary

Johnson & Johnson is hoping for approval of a supplemental BLA for once-weekly use of Procrit in chemotherapy patients by mid-2004

You may also be interested in...



J&J Procrit Gains Once-Weekly Dosing In Chemotherapy Patients

Johnson & Johnson's Procrit (epoetin alfa) approval for once-weekly dosing in chemotherapy patients should relieve one of the marketing challenges it has had in facing Amgen's Aranesp (darbepoetin)

J&J Procrit Gains Once-Weekly Dosing In Chemotherapy Patients

Johnson & Johnson's Procrit (epoetin alfa) approval for once-weekly dosing in chemotherapy patients should relieve one of the marketing challenges it has had in facing Amgen's Aranesp (darbepoetin)

J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount

Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call

Related Content

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel